血清CA19-9、MUC5AC、Exo-EphA2在胰腺癌与肿块型胰腺炎中的临床意义

Clinical Significance of Serum CA19-9, MUC5AC, and Exo-EphA2 in Pancreatic Cancer and Mass Pancreatitis

摘要

目的 分析血清CA19-9、黏蛋白5AC（MUC5AC）、外泌EphrinA型受体2（Exo-EphA2）对胰腺癌与肿块型胰腺炎的鉴别诊断价值及与影像学病理特征的相关性。方法 选取2022年1月~2023年6月于周口市中心医院就诊的82例胰腺癌患者作为观察组,选择同期41例肿块性胰腺炎患者作为对照组,比较2组及不同病理参数血清CA19-9、MUC5AC、Exo-EphA2水平,对其诊断价值进行分析,并进一步分析相关性。结果 研究组血清CA19-9、MUC5AC、Exo-EphA2水平较对照组明显增加（P<0.05）;不同病理学参数胰腺癌患者血清CA19-9、MUC5AC、Exo-EphA2水平比较：低分化高于中高分化,Ⅰ~Ⅱ期低于Ⅲ~Ⅳ期,有远处转移高于无远处转移（P<0.05）;CA19-9、MUC5AC、Exo-EphA2水平与远处转移、TNM分期呈正相关,与分化程度呈负相关（P<0.05）;血清CA19-9、MUC5AC、Exo-EphA2水平联合诊断胰腺癌的AUC为0.802,均高于各指标单独诊断。结论 血清CA19-9、MUC5AC、Exo-EphA2水平与胰腺癌病理学参数存在一定关系,联合检测可显著提升在胰腺癌、肿块型胰腺癌中的鉴别诊断价值。

Abstract

Objective To analyze the differential diagnostic value of serum CA19-9, mucin 5AC (MUC5AC), and exocytosis Ephrin type A receptor 2 (Exo-EphA2) for pancreatic adenocarcinoma and mass-type pancreatitis, and the correlation with imaging pathological features. Methods A total of 82 patients with pancreatic cancer who were treated in Zhoukou Central Hospital from January 2022 to June 2023 were selected as the observation group, and 41 patients with mass pancreatitis were selected as the control group during the same period. The diagnostic values of the 2 groups and the different pathological parameters of serum CA19-9, MUC5AC, and Exo-EphA2 were compared to analyze their diagnostic values and to analyze the correlation further. Results Serum CA19-9, MUC5AC, and Exo-EphA2 levels were significantly increased in the study group compared with the control group (P<0.05). Comparison of serum CA19-9, MUC5AC, and Exo-EphA2 levels in patients with pancreatic cancer of different pathological parameters. Low differentiation was higher than middle and high differentiation, stage Ⅰ~Ⅱ was lower than Ⅲ~Ⅳ, and distant metastasis was higher than no distant metastasis (P<0.05). The levels of CA19-9, MUC5AC and Exo-EphA2 were positively correlated with distant metastasis and TNM stage, and negatively correlated with the degree of differentiation (P<0.05). The AUC for the combined diagnosis of pancreatic cancer with serum CA19-9, MUC5AC and Exo-EphA2 levels was 0.802, which was higher than that of each index alone. Conclusion There is a relationship between serum CA19-9, MUC5AC, and Exo-EphA2 levels and pathological parameters of pancreatic cancer, and the combined test can significantly enhance the differential diagnostic value in pancreatic cancer and mass-type pancreatic cancer.

关键词

CA19-9 / 黏蛋白5AC / 外泌EphrinA型受体2 / 胰腺癌

Key words

CA19-9 / MUC5AC / Exo-EphA2 / pancreatic cancer

[1] 张浩,朱蒙蒙,周健,等. 基于CT影像特征用于鉴别具有慢性胰腺炎病史的胰腺癌与肿块型慢性胰腺炎的列线图构建[J]. 中华胰腺病杂志,2021,21(6):441-447.
[2] 邱江东,朱瑞哲,陈浩,等. 《中国胰腺癌新辅助治疗指南(2020版)》解读[J]. 中华外科杂志,2021,59(3):232-236.
[3] 展翰翔,李永政,胡三元. 胰腺癌病人组织消耗与围术期处理策略[J]. 中华消化外科杂志,2021,20(4):407-413.
[4] 张太平,刘悦泽,曹喆. 新辅助治疗背景下胰腺癌扩大切除术的应用价值[J]. 中华外科杂志,2020,58(7):481-485.
[5] 杨新焕,闫东,张斯佳,等. 磁共振灌注成像对胰腺癌与肿块型慢性胰腺炎的鉴别诊断价值[J]. 癌症进展,2020,18(1):88-91.
[6] 欧阳向柳,韩云霞,郑立春,等. 肿块型自身免疫性胰腺炎与胰腺导管腺癌的超声及超声造影表现分析[J]. 临床肝胆病杂志,2022,38(6):1351-1355.
[7] 郭立仪,邓明辉. CA19-9、CA125及CEA联合磁共振成像诊断胰腺癌的价值研究[J]. 中国实用医药,2021,16(15):82-84.
[8] 郎韧,吕少诚,贺强. 伴有门静脉系统侵犯的胰腺癌外科治疗[J]. 中华肝胆外科杂志,2020,26(11):801-804.
[9] 田丽,暴晓琳,马青素. 血清CA19-9、CA50、CA242、CA125及CEA联合检测在Ⅰ~Ⅲ期可切除胰腺癌诊断中的应用价值[J]. 临床医学,2020,40(10):36-37.
[10] 孙静. 肿瘤标志物CA19-9、CA242、CEA和CA125联合检测在胰腺癌诊断中的意义[J]. 中国医药指南,2020,18(18):180-181.
[11] 陈婷,朱雄,陈海,等. 不同临床特征胰腺癌患者CA19-9、CA242及CEA水平及其临床意义[J]. 实用癌症杂志,2020,35(6):996-999.
[12] 袁姣姣,余洋,向仍运. 胰腺癌患者的血清Exo-EphA2、CPA1和CA19-9表达及其临床意义[J]. 国际消化病杂志,2022,42(6):372-377.
[13] 魏倩,李泽,冯红蕾. 胰腺癌患者血清外泌体酪氨酸蛋白激酶受体EphA2蛋白表达变化及其意义[J]. 山东医药,2021,61(9):31-34.
[14] 李鑫,赵爱光,杨金祖,等. 基于“津液”及“痰饮”理论探讨黏蛋白5AC在恶性肿瘤中的作用[J]. 辽宁中医杂志,2020,47(8):51-54.
[15] 李祥苏,王冬冬,吴旭东. 血清MUC5AC和CA199联合检测在胰腺癌诊断中的作用[J]. 现代肿瘤医学,2022,30(5):852-855.